Biosimilars: Beyond the Switch with Dr.Carter Thorne PART 1

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.
 

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

 

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

 

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

 

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. 

 

Episode Learning Objectives

 

 

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

 

By the end of this episode, listeners should be able to:

Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.Discuss the future of TNFA-i and RWE in clinical practice.Identify factors to consider when differentiating between biosimilars during a switch.Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

📻www.skinandjoints.ca

✉️[email protected]